Clinical Trials Logo

Clinical Trial Summary

Chronic hepatitis C virus (HCV) infection and nonalcoholic fatty liver disease (NAFLD) are characterized by a spectrum of pathological conditions ranging from an early stage of inflammation and fibrosis up to more advanced disease conditions, such as hepatocellular carcinoma. The prevalence of NAFLD is between 10 and 25% of the population, with large differences in age and ethnic groups, while it is well known that HCV infection is a major cause of chronic liver disease in Western countries.

For both diseases the progression of liver damage is in close correlation with the lifestyle of patients (eg., nutrition, physical activity, ingestion of alcohol, etc.). In fact, it was shown that feeding imbalances may have implications in altering the normal immune functions of the subjects, suggesting that the metabolic and the immune systems are closely related to each other. Although it is well known the negative role of obesity on the progression of NAFLD and HCV liver diseases, the pathogenic mechanism underlying the alterations related to the immune response is not yet fully understood. Insulin resistance, altered lipid metabolism, lipid peroxidation, oxidative stress and mitochondrial alterations are pathogenic mechanisms that induce liver damage and its progression, both in NAFLD and in HCV infection.

Recent studies suggest that the evolution of viral infections and chronic inflammation in NAFLD are deeply influenced by CD4+ T helper cells expressing IL-17 , defined as T helper 17 (Th17) cells. Broadening the knowledge on the role of diet in the course of NAFLD and HCV infection in the activation of Th17 cells and in the alteration of some of their functions, will allow to shed light on the pathogenic mechanisms underlying the progression of immune-mediated diseases. Moreover, this investigation will allow to understand whether Th17 cells may have a role in the diminished response to therapy in patients who have high cholesterol levels.

If the results will confirm our hypothesis, this study will provide useful informations for the clinical management of patients with both steatosis and chronic HCV infection. The data obtained can also be used for the development of new therapeutic strategies directed to modulate the antiviral immune response.

All patients will undergo clinical and instrumental assessment depending on the type of pathology. Patients will be required to follow a normocaloric low cholesterol diet for a period of 30 days.

The prospective clinical study does not present any form of additional risk for the patients and will be conducted in accordance with the principles established by the Declaration of Helsinki and with the standards of Good Clinical Practice (GCP). The study does not require any additional costs.


Clinical Trial Description

n/a


Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02038387
Study type Interventional
Source University of Roma La Sapienza
Contact Vincenzo Barnaba, MD
Phone +39-064453994
Email vincenzo.barnaba@uniroma1.it
Status Recruiting
Phase N/A
Start date July 2012

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02248311 - "Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population N/A
Completed NCT01277237 - The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease Phase 3
Active, not recruiting NCT04442620 - Prevention and Reversion of NAFLD in Obese Patients With Metabolic Syndrome by Mediterranean Diet and Physical Activity N/A
Completed NCT01999101 - Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Phase 2
Completed NCT01327443 - Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease N/A
Active, not recruiting NCT01482065 - The Sleep, Liver Evaluation and Effective Pressure Study N/A
Completed NCT03135873 - Mastiha Treatment for Obese With NAFLD Diagnosis N/A
Completed NCT02686476 - Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes N/A
Completed NCT02820285 - Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASH N/A
Completed NCT01556113 - Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease N/A
Recruiting NCT06080386 - UDFF Performance Evaluation ((Ultrason Derived Fat Fraction)
Terminated NCT02134522 - The Role of Obstructive Sleep Apnea in Children With Fatty Liver Disease N/A
Completed NCT01553500 - Glucomannan Effects on Children With Non-alcoholic Fatty Liver Disease Phase 2
Completed NCT05426382 - A Digital Solution for Individuals With Non Alcoholic Fatty Liver Disease N/A
Completed NCT03300661 - Non Alcoholic Fatty Liver Disease: Nutritional Epidemiology and Lifestyle Medicine N/A
Not yet recruiting NCT02178839 - The Effect of Oral β- Glucan Supplement on Appetite and Insulin Resistance in Non Alcoholic Fatty Liver Disease N/A
Completed NCT01634048 - The Effect of Protein-enriched Diet on Body Composition and Appetite N/A
Completed NCT01874249 - Non Invasive Assessment of Liver Fibrosis in Fatty Liver Disease N/A
Completed NCT01966627 - Genetics of Fatty Liver Disease in Children N/A
Terminated NCT01842282 - Amlexanox for Type 2 Diabetes and Obesity Phase 2